{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,25]],"date-time":"2026-07-25T23:00:56Z","timestamp":1785020456669,"version":"3.55.0"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,7,25]]},"DOI":"10.7759\/cureus.113371","type":"journal-article","created":{"date-parts":[[2026,7,25]],"date-time":"2026-07-25T22:25:47Z","timestamp":1785018347000},"source":"Crossref","is-referenced-by-count":0,"title":["Comparative Cardiovascular Pharmacovigilance of Semaglutide and Tirzepatide: A Food and Drug Administration Adverse Event Reporting System (FAERS) Database Analysis (2022-2026)"],"prefix":"10.7759","author":[{"given":"Abhinandan","family":"Singla","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gurnoor","family":"Kaur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gurpreet","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shivansh","family":"Luthra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chirag","family":"Lodha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Omar","family":"Alneser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammed S","family":"Alo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Syed S","family":"Ali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammad","family":"Zulqarnain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.7326\/M20-0864","article-title":"Comparative effectiveness of glucose-lowering drugs for type 2 diabetes: a systematic review and network meta-analysis","volume":"173","author":"Tsapas A","year":"2020","unstructured":"Tsapas A, Avgerinos I, Karagiannis T, et al.. Comparative effectiveness of glucose-lowering drugs for type 2 diabetes: a systematic review and network meta-analysis. Ann Intern Med. 2020, 173:278-86. 10.7326\/M20-0864","journal-title":"Ann Intern Med"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1016\/j.molmet.2020.101102","article-title":"GLP-1 receptor agonists in the treatment of type 2 diabetes - state-of-the-art","volume":"46","author":"Nauck MA","year":"2021","unstructured":"Nauck MA, Quast DR, Wefers J, Meier JJ. GLP-1 receptor agonists in the treatment of type 2 diabetes - state-of-the-art. Mol Metab. 2021, 46:101102. 10.1016\/j.molmet.2020.101102","journal-title":"Mol Metab"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjcard.2025.09.039","article-title":"GLP-1 receptor agonists and cardiovascular outcomes in adults with diabetes and peripheral artery disease: an updated systematic review and meta-analysis","volume":"258","author":"Shuja SH","year":"2026","unstructured":"Shuja SH, Shuja MH, Shaukat A, et al.. GLP-1 receptor agonists and cardiovascular outcomes in adults with diabetes and peripheral artery disease: an updated systematic review and meta-analysis. Am J Cardiol. 2026, 258:268-75. 10.1016\/j.amjcard.2025.09.039","journal-title":"Am J Cardiol"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2307563","article-title":"Semaglutide and cardiovascular outcomes in obesity without diabetes","volume":"389","author":"Lincoff AM","year":"2023","unstructured":"Lincoff AM, Brown-Frandsen K, Colhoun HM, et al.. Semaglutide and cardiovascular outcomes in obesity without diabetes. N Engl J Med. 2023, 389:2221-32. 10.1056\/NEJMoa2307563","journal-title":"N Engl J Med"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1607141","article-title":"Semaglutide and cardiovascular outcomes in patients with type 2 diabetes","volume":"375","author":"Marso SP","year":"2016","unstructured":"Marso SP, Bain SC, Consoli A, et al.. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med. 2016, 375:1834-44. 10.1056\/NEJMoa1607141","journal-title":"N Engl J Med"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1007\/s13300-020-00981-0","article-title":"The role of tirzepatide, dual GIP and GLP-1 receptor agonist, in the management of type 2 diabetes: the SURPASS clinical trials","volume":"12","author":"Min T","year":"2021","unstructured":"Min T, Bain SC. The role of tirzepatide, dual GIP and GLP-1 receptor agonist, in the management of type 2 diabetes: the SURPASS clinical trials. Diabetes Ther. 2021, 12:143-57. 10.1007\/s13300-020-00981-0","journal-title":"Diabetes Ther"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2107519","article-title":"Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes","volume":"385","author":"Fr\u00edas JP","year":"2021","unstructured":"Fr\u00edas JP, Davies MJ, Rosenstock J, et al.. Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes. N Engl J Med. 2021, 385:503-15. 10.1056\/NEJMoa2107519","journal-title":"N Engl J Med"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2206038","article-title":"Tirzepatide once weekly for the treatment of obesity","volume":"387","author":"Jastreboff AM","year":"2022","unstructured":"Jastreboff AM, Aronne LJ, Ahmad NN, et al.. Tirzepatide once weekly for the treatment of obesity. N Engl J Med. 2022, 387:205-16. 10.1056\/NEJMoa2206038","journal-title":"N Engl J Med"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1097\/XCE.0000000000000265","article-title":"Can glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors help in mitigating the risk of atrial fibrillation in patients with diabetes?","volume":"11","author":"Thotamgari SR","year":"2022","unstructured":"Thotamgari SR, Grewal US, Sheth AR, Babbili A, Dominic P. Can glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors help in mitigating the risk of atrial fibrillation in patients with diabetes?. Cardiovasc Endocrinol Metab. 2022, 11:e0265. 10.1097\/XCE.0000000000000265","journal-title":"Cardiovasc Endocrinol Metab"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1016\/j.therap.2016.02.016","article-title":"Pharmacoepidemiology and its input to pharmacovigilance","volume":"71","author":"Faillie JL","year":"2016","unstructured":"Faillie JL, Montastruc F, Montastruc JL, Pariente A. Pharmacoepidemiology and its input to pharmacovigilance. Therapie. 2016, 71:211-6. 10.1016\/j.therap.2016.02.016","journal-title":"Therapie"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1002\/pds.677","article-title":"Use of proportional reporting ratios (PRRs) for signal generation from spontaneous adverse drug reaction reports","volume":"10","author":"Evans SJ","year":"2001","unstructured":"Evans SJ, Waller PC, Davis S. Use of proportional reporting ratios (PRRs) for signal generation from spontaneous adverse drug reaction reports. Pharmacoepidemiol Drug Saf. 2001, 10:483-6. 10.1002\/pds.677","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.3390\/ph19010136","article-title":"Comparative safety of GLP-1 receptor agonists across gastrointestinal, renal and pancreatic systems","volume":"19","author":"Shokr H","year":"2026","unstructured":"Shokr H, Mekkawy M, Hindi A. Comparative safety of GLP-1 receptor agonists across gastrointestinal, renal and pancreatic systems. Pharmaceuticals (Basel). 2026, 19:136. 10.3390\/ph19010136","journal-title":"Pharmaceuticals (Basel)"},{"key":"ref13","unstructured":"FDA Adverse Event Monitoring System (AEMS) quarterly data extract files. (2026). Accessed. 2026: https:\/\/fis.fda.gov\/extensions\/FPD-QDE-FAERS\/FPD-QDE-FAERS.html."},{"key":"ref14","article-title":"Introductory Guide: MedDRA Version 26.0","year":"2023","unstructured":"Introductory Guide. MedDRA Version 26.0. International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use, Geneva, Switzerland; 2023."},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1002\/pds.3891","article-title":"Guidelines for good pharmacoepidemiology practice (GPP)","volume":"25","year":"2016","unstructured":"Guidelines for good pharmacoepidemiology practice (GPP). Pharmacoepidemiol Drug Saf. 2016, 25.2-10. 10.1002\/pds.3891","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"ref16","unstructured":"Ozempic (semaglutide) injection, for subcutaneous use. (2017). Accessed. 2026: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2017\/209637lbl.pdf."},{"key":"ref17","unstructured":"Wegovy (semaglutide) injection, for subcutaneous use. (2021). Accessed. 2026: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2021\/215256s000lbl.pdf."},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehz486","article-title":"2019 ESC guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD","volume":"41","author":"Cosentino F","year":"2020","unstructured":"Cosentino F, Grant PJ, Aboyans V, et al.. 2019 ESC guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. Eur Heart J. 2020, 41:255-323. 10.1093\/eurheartj\/ehz486","journal-title":"Eur Heart J"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2306963","article-title":"Semaglutide in patients with heart failure with preserved ejection fraction and obesity","volume":"389","author":"Kosiborod MN","year":"2023","unstructured":"Kosiborod MN, Abildstr\u00f8m SZ, Borlaug BA, et al.. Semaglutide in patients with heart failure with preserved ejection fraction and obesity. N Engl J Med. 2023, 389:1069-84. 10.1056\/NEJMoa2306963","journal-title":"N Engl J Med"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmet.2016.06.009","article-title":"The cardiovascular biology of glucagon-like peptide-1","volume":"24","author":"Drucker DJ","year":"2016","unstructured":"Drucker DJ. The cardiovascular biology of glucagon-like peptide-1. Cell Metab. 2016, 24:15-30. 10.1016\/j.cmet.2016.06.009","journal-title":"Cell Metab"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-022-01707-4","article-title":"Tirzepatide cardiovascular event risk assessment: a pre-specified meta-analysis","volume":"28","author":"Sattar N","year":"2022","unstructured":"Sattar N, McGuire DK, Pavo I, Weerakkody GJ, Nishiyama H, Wiese RJ, Zoungas S. Tirzepatide cardiovascular event risk assessment: a pre-specified meta-analysis. Nat Med. 2022, 28:591-8. 10.1038\/s41591-022-01707-4","journal-title":"Nat Med"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1002\/pds.3440","article-title":"Multi-country rapid adverse drug event assessment: the Asian Pharmacoepidemiology Network (AsPEN) antipsychotic and acute hyperglycaemia study","volume":"22","author":"Pratt N","year":"2013","unstructured":"Pratt N, Andersen M, Bergman U, et al.. Multi-country rapid adverse drug event assessment: the Asian Pharmacoepidemiology Network (AsPEN) antipsychotic and acute hyperglycaemia study. Pharmacoepidemiol Drug Saf. 2013, 22:915-24. 10.1002\/pds.3440","journal-title":"Pharmacoepidemiol Drug Saf"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/512858-comparative-cardiovascular-pharmacovigilance-of-semaglutide-and-tirzepatide-a-food-and-drug-administration-adverse-event-reporting-system-faers-database-analysis-2022-2026","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,25]],"date-time":"2026-07-25T22:25:49Z","timestamp":1785018349000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/512858-comparative-cardiovascular-pharmacovigilance-of-semaglutide-and-tirzepatide-a-food-and-drug-administration-adverse-event-reporting-system-faers-database-analysis-2022-2026"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,25]]},"references-count":22,"URL":"https:\/\/doi.org\/10.7759\/cureus.113371","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7,25]]}}}